Albuminuria: Associated With Heart Failure Severity and Impaired Clinical Outcomes

2020 ◽  
Vol 36 (4) ◽  
pp. 527-534 ◽  
Author(s):  
Mony Shuvy ◽  
Donna R. Zwas ◽  
Chaim Lotan ◽  
Andre Keren ◽  
Israel Gotsman
Life ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1006
Author(s):  
Ieva Kažukauskienė ◽  
Vaida Baltrūnienė ◽  
Ieva Rinkūnaitė ◽  
Edvardas Žurauskas ◽  
Dalius Vitkus ◽  
...  

Inflammation-related biomarkers are associated with clinical outcomes in mixed-etiology chronic heart failure populations. Inflammation-related markers tend to be higher in ischemic than in non-ischemic dilated cardiomyopathy (NI-DCM) patients, which might impact their prognostic performance in NI-DCM patients. Therefore, we aimed to assess the association of inflammation-related biomarkers with heart failure severity parameters and adverse cardiac events in a pure NI-DCM patient cohort. Fifty-seven patients with NI-DCM underwent endomyocardial biopsy. Biopsies were evaluated by immunohistochemistry for CD3+, CD45ro+, CD68+, CD4+, CD54+, and HLA-DR+ cells. Blood samples were tested for high-sensitivity C-reactive protein (hs-CRP), interleukin-6, tumor necrosis factor-α (TNF-α), soluble urokinase-type plasminogen activator receptor and adiponectin. During a five-year follow-up, twenty-seven patients experienced at least one composite adverse cardiac event: left ventricle assist device implantation, heart transplantation or death. Interleukin-6, TNF-α and adiponectin correlated with heart failure severity parameters. Patients with higher levels of interleukin-6, TNF-α, adiponectin or hs-CRP, or a higher number of CD3+ or CD45ro+ cells, had lower survival rates. Interleukin-6, adiponectin, and CD45ro+ cells were independently associated with poor clinical outcomes. All patients who had interleukin-6, TNF-α and adiponectin concentrations above the threshold experienced an adverse cardiac event. Therefore, a combination of these cytokines can identify high-risk NI-DCM patients.


Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Katherine C Michelis ◽  
Justin L Grodin ◽  
Lin Zhong ◽  
Ambarish Pandey ◽  
Kathleen Toto ◽  
...  

Introduction: Although patient-reported outcomes are increasingly emphasized, symptoms may be discordant to objective parameters of heart failure severity. The frequency of such discordance, associated characteristics, and its influence on clinical outcomes is unknown. Methods: This is a post-hoc analysis of the HF-ACTION trial (N=2062). Participants were divided by median baseline values for Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ, subjective measure) and V E /VCO 2 slope (objective measure) into 4 groups: “concordant-lower severity” (high KCCQ, low V E /VCO 2 slope), “concordant-higher severity” (low KCCQ, high V E /VCO 2 slope), “symptom magnifier” (low KCCQ, V E /VCO 2 slope), and “symptom minimizer” (high KCCQ, V E /VCO 2 slope). Baseline characteristics were compared, and the relationship between group and clinical outcomes over a median follow-up of 442 days was assessed in adjusted Cox models. Results: Discordance of patient-reported and objective illness severity was common (46%). Depression was more prevalent among symptom magnifiers (N=480) versus concordant-lower severity (N=566) and symptom minimizer (N=465) groups (30%, 18%, 14%, respectively; P<0.001). Compared to concordant-lower severity participants, those who were symptom magnifiers, symptom minimizers, or concordant-higher severity were at increased risk of hospitalization (Table). Concordant-higher severity participants and symptom minimizers, but not symptom magnifiers, were at an increased risk of death versus concordant-lower severity participants. Conclusion: A high rate of discordance was observed between patient-reported and objective heart failure severity. Depression was associated with symptom magnification. Hospitalization was influenced by patient-reported severity but mortality tracked more closely with objective data, highlighting potential limitations of static patient-reported outcomes for risk stratification.


Circulation ◽  
2003 ◽  
Vol 107 (10) ◽  
pp. 1396-1400 ◽  
Author(s):  
Darren Mansfield ◽  
David M. Kaye ◽  
Hanspeter Brunner La Rocca ◽  
Peter Solin ◽  
Murray D. Esler ◽  
...  

2018 ◽  
Vol 11 (9) ◽  
pp. e201800066 ◽  
Author(s):  
Evgeny A. Shirshin ◽  
Yury I. Gurfinkel ◽  
Simon T. Matskeplishvili ◽  
Maria L. Sasonko ◽  
Nikolai P. Omelyanenko ◽  
...  

ASAIO Journal ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Rebecca Cogswell ◽  
Jerry D. Estep ◽  
Raquel Araujo-Gutierrez ◽  
Maria Masotti ◽  
Valmiki Majaraj ◽  
...  

2013 ◽  
Vol 6 (1) ◽  
Author(s):  
Olarinde Jeffrey Ogunmola ◽  
Anthony Olubunmi Akintomide ◽  
Adeyemi Michael Olamoyegun

2011 ◽  
Vol 31 (5) ◽  
pp. 608-621 ◽  
Author(s):  
Ashley W. LeMaire ◽  
Amit Shahane ◽  
Tam K. Dao ◽  
Jeffrey L. Kibler ◽  
Jeffrey A. Cully

2004 ◽  
Vol 10 (4) ◽  
pp. S105 ◽  
Author(s):  
Geetha Bhat ◽  
Margaret Dugan ◽  
Jignesh Shah

Sign in / Sign up

Export Citation Format

Share Document